News | March 20, 2008

DIA, FDA and Heart Rhythm Society to Explore QT, Arrhythmia

March 21, 2008 — The Drug Information Association (DIA) will host an educational forum in conjunction with the FDA and the Heart Rhythm Society entitled 'QT and Arrhythmia Issues in Drug Development' from April 7-8, in Bethesda, MD, to focus on the new direction in the development of pharmaceutical agents for cardiac repolarization.

Specific areas of concentration will include:

• QT study design and analyses;
• the use of new methodologies including concentration-effect modeling;
• approaches to QT evaluation in Phase 3 when there is a QT signal;
• QT assessment in patient populations when healthy volunteers cannot be studies;
• QT assessment of biologic compounds;
• regulatory implications; and
• a special session on the science and clinical ramifications of QT shortening.

“The FDA is, of course, keenly interested in safety standards, and their involvement with this workshop means participants will gain first-hand knowledge of regulatory expectations such as how new preclinical or clinical biomarkers can gain regulatory acceptance,” said Program Chair Philip T. Sager, M.D., chief medical officer, CardioDX Inc.

Workshop content will be relevant to a variety of disciplines in drug development, including academic scientists, industry management, clinical project physicians, quality assurance directors, preclinical/discovery scientists, ECG safety data managers, ECG lab and equipment vendors, regulatory specialists and safety assessment personnel.

In addition to the two-day conference, a pre-event tutorial: An Introduction to QT Issues in Drug Development will be offered on April 6. The tutorial will provide attendees with the resources and information necessary to understand relevant concepts in the collection, analysis and interpretation of ECG parameters in their own clinical trials and to learn of the most recent developments in clinical interpretation of QT/QTc prolongation.

For more information: www.diahome.org

Related Content

News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
New FOURIER Analysis Examines How Low Cholesterol Can Safely Go
News | ESC| September 12, 2017
September 12, 2017 — Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with progressive
CANTOS Study Shows Reducing Inflammation Cuts Cardiovascular Disease, Lung Cancer Risk
News | ESC| September 12, 2017
September 12, 2017 — The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk b
COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies| September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals| September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies| August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Overlay Init